FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2025.07.018 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Thomas Aparicio und 15 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology department, Saint Louis Hospital, APHP, Université Paris Cité, Paris, France. Electronic address: thomas.aparicio@avc.aphp.fr. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma, Intestinal Neoplasms, Intestine, Small. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut National du Cancer.
Abstract (Originalsprache)
BACKGROUND: Small bowel adenocarcinoma (SBA) is rare. Palliative chemotherapy was evaluated mainly in retrospective studies. No randomized trial has been previously performed to evaluate front line chemotherapy in advanced SBA. METHODS: Randomized, non-comparative, open-label, multi-center phase II study to evaluate mFOLFOX (D1=D15: oxaliplatin 85 mg/m2, folinic acid: 400 mg/m2, 5FU bolus: 400 mg/m2 followed by 5FU: 2400 mg/m2 IV infusion over 46 h) and mFOLFIRINOX (mFOLFOX plus irinotecan 180 mg/m2, without 5FU bolus) in the first line treatment of unresectable locally advanced or metastatic SBA. Ampullary carcinoma and MSI-H/dMMR SBA are excluded. The primary endpoint is to assess the percentage of patients alive without progression at 8 months. In each arm, assuming a null hypothesis of 40 % of patients free of progression at 8 months, and a target percentage of 55 %, 65 patients per arm are needed with 85 % power and 10 % one-sided type I error. Randomizations started in February 2024.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology department, Saint Louis Hospital, APHP, Université Paris Cité, Paris, France. Electronic address: thomas.aparicio@avc.aphp.fr.
- Oncology department, Lille University Hospital, Lille, France.
- Digestive oncology, European Georges Pompidou Hospital, APHP, Université Paris Cité, Paris, France.
- Oncology department, Institut Paoli Calmette, Marseille, France.
- Fédération Francophone de Cancérologie Digestive (FFCD), EPICAD INSERM LNC-UMR 1231, Faculté de Médecine, University of Burgundy Europe, Dijon, France.
- Unit of Medical Oncology 1, Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Gruppo Oncologico del Nord Ovest (GONO-GI Foundation), Genova, Italy.
Förderung
- Institut National du Cancer
Zitieren
APA
Aparicio, T., Turpin, A., Zaanan, A., de la Fouchardière, C., Le Malicot, K., Lonardi, S., Modest, D. P., Wilson, R., Cremolini, C., Ballhausen, A., Graham, J., Kurreck, A., Guarssifi, M., Svrcek, M., Laurent-Puig, P., & Manfredi, S. (2025). FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.07.018
Vancouver
Aparicio T, Turpin A, Zaanan A, de la Fouchardière C, Le Malicot K, Lonardi S, et al. FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.07.018
BibTeX
@article{Aparicio2025,
author = {Aparicio, Thomas and Turpin, Anthony and Zaanan, Aziz and de la Fouchardière, Christelle and Le Malicot, Karine and Lonardi, Sara and Modest, Dominik Paul and Wilson, Richard and Cremolini, Chiara and Ballhausen, Alexej and Graham, Janet and Kurreck, Annika and Guarssifi, Meriem and Svrcek, Magali and Laurent-Puig, Pierre and Manfredi, Sylvain},
title = {FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2025.07.018}
}
EUVIMED